DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Harrington KJ, Andtbacka RH, Collichio F. et al.
Efficacy and safety of talimogene laherparepvec vs. granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial.
Onco Targets Ther 2016;
9: 7081-7093
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.